Du Pont Merck Pharmaceuticalsis poised to become the second company with a brain SPECT agenton the U.S. market. The Food and Drug Administration has sentDu Pont an "approvable" letter for Neurolite, its technetium-taggedbrain imaging agent.
Du Pont Merck Pharmaceuticalsis poised to become the second company with a brain SPECT agenton the U.S. market. The Food and Drug Administration has sentDu Pont an "approvable" letter for Neurolite, its technetium-taggedbrain imaging agent.
Neurolite is indicated for brain perfusion studies in strokepatients. An FDA advisory committee recommended Neurolite forapproval last year (SCAN 6/30/93). Final FDA approval will begiven upon mutual agreement of labeling and phase-four studies,according to the company. Neurolite has regulatory approval inJapan and several European countries.
Neurolite's arrival would double the number of commerciallyavailable brain SPECT agents in the U.S. Amersham's technetium-labeledCeretec is currently the only brain SPECT agent being activelymarketed.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 3
August 2nd 2025In the last of a three-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, share additional insights on practical considerations and potential challenges in integrating abbreviated breast MRI into clinical practice, and offer their thoughts on future research directions.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 2nd 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
Twenty Years of CT Colonography for Colorectal Cancer Screening: What the Research Reveals
August 2nd 2025Computed tomography colonography (CTC) demonstrated a 91.6 percent positive predictive value (PPV) for polyps > 6 mm, according to new research involving over 9,000 patients who underwent CTC for primary asymptomatic colorectal cancer screening.